Vioxx (rofecoxib), manufactured by Merck & Co is a COX-2 inhibitor medication prescribed for acute pain in adults and for relief of the signs and symptoms of osteoarthritis or arthritis, and sometimes just muscle pain. It has been attributed to cardio vascular events. But it is also one of Merck’s most profitable drugs and the subject of massive advertising spending.
On 9/17/2001 a Warning Letter was issued by the Department of Health and Human Services to Raymond V. Gilmartin, President and CEO of Merck. That letter warns of advertising errors that minimize the “potentially serious cardiovascular findings that were observed in the Vioxx Gastrointestinal Outcomes Research (VIGOR) study, and thus misrepresents the safety profile for Vioxx.”
Finally, on September 30,2004, Merck &Co announced a voluntary withdrawl of Vioxx from the US market due to “safety concerns.” A link to the FDA Public Health Advisory is as follows: http://www.fda.gov/cder/drug/infopage/vioxx/
Anyone having experienced a heart attack, stroke, pulmonary embolism, or other cardio vascular event should contact us immediately.
Disclaimer:
Colorado Trial Attorney Disclaimer: Denver and Breckenridge
securities and investment fraud, business lawsuits,
construction injuries, medical malpractice, wrongful
death, brain injury, personal injury, pharmaceutical
litigation, and/or other legal information offered herein
by Gempeler Trial Attorneys is not formal legal advice,
nor the formation of an attorney client relationship.
The information provided on Gempeler Trial Lawyers'
website is intended to educate the visitors and does
not constitute legal advice. Each case is different
and the outcome of your case will depend on the merits
of your factual situation and applicable law. An Attorney-Client
relationship is not created by visiting this web site.
No Attorney-Client relationship is created until a retainer
agreement is signed.
Home
| Areas of Practice | News & Alerts | FAQ's | About
Us | Speeches & Articles
| Calendar | Contact
Us | Site
Map |
